Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Systemic scleroderma
ADR ID BADD_A11010
ADR Hierarchy
07      Gastrointestinal disorders
07.11      Gastrointestinal conditions NEC
07.11.02      Oesophageal disorders NEC
07.11.02.009      Systemic scleroderma
10      Immune system disorders
10.04      Autoimmune disorders
10.04.07      Scleroderma and associated disorders
10.04.07.009      Systemic scleroderma
15      Musculoskeletal and connective tissue disorders
15.06      Connective tissue disorders (excl congenital)
15.06.01      Connective tissue disorders NEC
15.06.01.024      Systemic scleroderma
23      Skin and subcutaneous tissue disorders
23.03      Epidermal and dermal conditions
23.03.02      Connective tissue disorders
23.03.02.025      Systemic scleroderma
24      Vascular disorders
24.03      Vascular disorders NEC
24.03.03      Vascular malformations and acquired anomalies
24.03.03.052      Systemic scleroderma
Description A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA. [MeSH]
MedDRA Code 10078638
MeSH ID D012595; D045743
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Acrosclerosis | Diffuse scleroderma | Diffuse systemic sclerosis | Generalized scleroderma | Progressive systemic sclerosis | Systemic sclerosis | Generalised scleroderma | Systemic scleroderma | Systemic sclerosis sine scleroderma | Scleroderma overlap syndrome | Scleroderma, Systemic | Systemic Sclerosis | Sclerosis, Systemic | Systemic Scleroderma
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00100Ambrisentan0.000325%
BADD_D00285Bosentan0.000542%
BADD_D00349Capecitabine0.000246%
BADD_D00364Carboplatin0.000168%
BADD_D00788Epoprostenol0.000082%
BADD_D00931Fluorouracil0.000184%
BADD_D01257Letrozole0.000527%
BADD_D01336Macitentan0.000181%
BADD_D01431Methylphenidate0.000082%
BADD_D01834Prednisone0.000018%
BADD_D02006Selexipag0.000164%
BADD_D02268Treprostinil0.000263%
BADD_D02470Nintedanib0.000336%
The 1th Page    1    Total 1 Pages